The median life expectancy after a first coronary artery bypass is about 18 years, based on 30-year follow-up data from one of the longest studies ever conducted on the procedure. But that number is an average across all patients and all graft types. How long your bypass actually lasts depends heavily on which blood vessels were used, how well you manage cholesterol and blood sugar afterward, and your age at the time of surgery.
How Long Different Graft Types Last
Not all bypass grafts are created equal. Surgeons typically use a combination of blood vessels, and each type has a different track record for staying open over time.
The gold standard is the left internal mammary artery, a vessel that runs along the inside of the chest wall. This graft stays open in roughly 85% to 95% of patients at the 10-year mark. Because it’s already an artery, it resists the buildup of plaque far better than vein grafts do. Almost every bypass surgery uses this graft for the most important coronary artery, the one that supplies the largest portion of the heart.
The most common secondary graft is the saphenous vein, taken from the leg. These grafts have a 10-year patency rate of about 61%, meaning roughly 4 in 10 will have narrowed significantly or closed entirely by the decade mark. Vein grafts are more vulnerable because veins weren’t designed to handle the higher pressures of arterial blood flow, so they develop thickening and disease over time.
The radial artery, taken from the forearm, falls between these two. A combined analysis of randomized trials published in the New England Journal of Medicine found that radial artery grafts had less than half the risk of occlusion compared to saphenous vein grafts at five years. They were also associated with a 50% lower rate of needing repeat procedures. Surgeons increasingly favor this option as a second graft when anatomy allows it.
Early Graft Failure
A small percentage of grafts fail within the first year. Previous studies have reported 1-year vein graft failure rates of 10% to 20%, though more recent data using CT imaging to catch even symptom-free blockages found an overall early failure rate closer to 5%. The most common cause in the first month is blood clot formation inside the graft. Risk factors for early failure include the grafting technique used and developing an irregular heart rhythm (atrial fibrillation) after surgery.
What Determines How Long Your Bypass Lasts
Five factors show up consistently across studies as the strongest predictors of long-term survival after bypass surgery: age at the time of surgery, heart pumping strength (ejection fraction), diabetes, kidney function, and history of stroke.
Age matters the most in raw terms. Twenty-year survival after bypass is about 55% for patients younger than 50 at the time of surgery, 38% for those in their 50s, 22% for those in their 60s, and 11% for those over 70. These numbers reflect both graft longevity and the natural aging process.
Diabetes has a dramatic impact. In one large study, 20-year survival was 49% for people without diabetes compared to just 31% for those with it. Diabetes accelerates disease inside the grafts and raises the risk of infection and kidney complications after surgery. Blood sugar control before and after the procedure matters too. Patients with progressively higher long-term blood sugar levels (measured by HbA1c) had survival rates at five years of 89%, 86%, 83%, and 79% as their sugar control worsened across each group.
Heart pumping strength before surgery is another strong predictor. Ten-year survival was about 62% for patients with normal pumping function, but dropped to 37% for those with severely weakened hearts. High blood pressure also takes a toll: 20-year survival was 41% without hypertension and 27% with it.
How Cholesterol Management Protects Your Grafts
Aggressive cholesterol lowering after bypass surgery is one of the most effective ways to extend graft life. This isn’t just about general heart health. Cholesterol-lowering medications directly slow the buildup of disease inside the grafts themselves.
One landmark trial found that keeping LDL cholesterol below 100 mg/dL significantly slowed vein graft disease progression. Over 7.5 years of follow-up, intensive cholesterol lowering led to a 30% reduction in the need for repeat procedures and a 24% decrease in serious cardiac events compared to moderate treatment. Imaging studies help explain why: grafts in patients with LDL above 100 showed visible plaque and clot, while those with LDL below 80 had none.
Graft patency in the first year tells a similar story. Patients who achieved LDL below 100 had a 96.5% graft patency rate at one year, compared to 83.3% for those with higher levels. Beyond two years after surgery, patients on lower-intensity cholesterol treatment had nearly double the rate of major cardiac events compared to those on higher-intensity treatment (9.1% versus 5.3%).
When Grafts Start to Fail: Warning Signs
Graft narrowing often develops gradually and can be silent for years. When symptoms do appear, they typically mirror the original heart disease that led to surgery in the first place: chest pain or pressure, shortness of breath during activity, unusual fatigue, or reduced exercise tolerance. More urgent signs include chest pain at rest, pain radiating to the arms, neck, or jaw, cold sweats, lightheadedness, or sudden difficulty breathing.
Many patients with failing grafts don’t have dramatic symptoms. Instead, they notice a slow return of the limitations they had before surgery. Routine follow-up with stress testing or imaging helps catch graft disease before it causes a heart attack.
What Happens If a Graft Fails
When a bypass graft narrows or closes, the two main options are placing a stent through a catheter or performing a second bypass surgery. A systematic review comparing these approaches found that repeat bypass surgery is associated with better long-term survival and a lower chance of needing yet another procedure. However, stenting is less invasive and carries lower short-term risk, so it’s often the first choice for single-graft problems.
In the longest follow-up study available, 94% of patients eventually needed some form of repeat intervention over 30 years. This underscores that bypass surgery, while highly effective, is a treatment for a progressive disease rather than a permanent cure. The grafts buy time, and the lifestyle and medical management after surgery determines how much time they buy.